Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy.
[esophageal squamous cell carcinoma]
There
is
increasing
evidence
that
the
presence
of
an
inflammation
-based
prognostic
score
(
modified
Glasgow
prognostic
score
,
mGPS
)
is
associated
with
survival
in
patients
with
advanced
cancer
.
This
study
aimed
to
assess
whether
the
mGPS
has
prognostic
value
in
patients
with
thoracic
esophageal
squamous
cell
carcinoma
undergoing
chemoradiotherapy
.
A
total
of
212
patients
undergoing
chemoradiotherapy
for
newly-diagnosed
esophageal
squamous
cell
carcinoma
between
October
,
2006
and
December
,
2011
were
retrospectively
analyzed
.
Serum
C-
reactive
protein
(
CRP
)
and
albumin
were
measured
before
initiation
of
treatment
.
The
relationships
between
the
mGPS
and
other
relevant
variables
including
white
blood
cell
count
,
neutrophilic
granulocyte
count
,
platelet
count
,
hemoglobin
,
bilirubin
,
aspartate
aminotransferase
(
AST
)
,
alanine
aminotransferase
(
ALT
)
and
lactate
dehydrogenase
(
LDH
)
were
analyzed
.
Overall
survival
(
OS
)
and
progression-free
survival
(
PFS
)
were
calculated
.
Significant
prognostic
factors
were
identified
using
univariate
and
multivariate
analyses
.
Three
-
year
OS
for
all
patients
was
24
.
6
%
;
3
-
year
PFS
was
21
.
3
%
.
Patients
with
a
mGPS
of
0
,
1
and
2
were
90
,
78
,
44
,
respectively
.
Higher
mGPS
was
related
to
higher
white
blood
cell
,
neutrophilic
granulocyte
and
platelet
counts
,
and
lower
total
bilirubin
.
T
stage
,
M
stage
and
mGPS
were
independent
prognostic
indicators
for
OS
;
T
stage
,
M
stage
,
mGPS
and
platelet
count
were
independent
prognostic
indicators
for
PFS
.
Pretreatment
mGPS
is
an
easily
measurable
significant
prognostic
factor
and
can
be
used
in
combination
with
conventional
TNM
staging
to
predict
survival
in
patients
with
squamous
cell
carcinoma
undergoing
chemoradiotherapy
.
Diseases
Validation
Diseases presenting
"cancer"
symptom
achondroplasia
acute rheumatic fever
adrenal incidentaloma
alpha-thalassemia
benign recurrent intrahepatic cholestasis
cadasil
canavan disease
carcinoma of the gallbladder
cholangiocarcinoma
coats disease
congenital adrenal hyperplasia
congenital diaphragmatic hernia
cowden syndrome
cushing syndrome
cutaneous mastocytosis
dedifferentiated liposarcoma
dystrophic epidermolysis bullosa
epidermolysis bullosa simplex
erdheim-chester disease
erythropoietic protoporphyria
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
familial hypocalciuric hypercalcemia
familial mediterranean fever
gm1 gangliosidosis
heparin-induced thrombocytopenia
hereditary cerebral hemorrhage with amyloidosis
hirschsprung disease
hodgkin lymphoma, classical
inclusion body myositis
junctional epidermolysis bullosa
kabuki syndrome
kallmann syndrome
kindler syndrome
lamellar ichthyosis
liposarcoma
locked-in syndrome
lymphangioleiomyomatosis
monosomy 21
neuralgic amyotrophy
oculocutaneous albinism
oligodontia
oral submucous fibrosis
papillon-lefèvre syndrome
pendred syndrome
pleomorphic liposarcoma
primary effusion lymphoma
proteus syndrome
pyomyositis
pyruvate dehydrogenase deficiency
severe combined immunodeficiency
sneddon syndrome
systemic capillary leak syndrome
triple a syndrome
von hippel-lindau disease
waldenström macroglobulinemia
well-differentiated liposarcoma
werner syndrome
wiskott-aldrich syndrome
wolf-hirschhorn syndrome
x-linked adrenoleukodystrophy
This symptom has already been validated